FDA E&M Division Director Is Lipid Drug Team Leader Orloff
FDA's Endocrine & Metabolic Drug Products Division Director David Orloff, MD, brings six years of experience within the E&M division in reviewing lipid-regulating agents.
You may also be interested in...
FDA Office of Drug Evaluation II Director John Jenkins, MD, is serving as acting director of FDA's Endocrine & Metabolic Drug Products Division following the departure Solomon Sobel, MD, to the Office of Review Management.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials